search
Back to results

China Salt Substitute Study in Tibet (CSSS-Tibet)

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Regular Salt
Salt Substitute
Sponsored by
The George Institute for Global Health, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Diet Therapy, Sodium Chloride, Dietary, Tibet, Aged

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 40 years or older
  • Resident of Yangbajing Township and Gongtang Village in Tibetan Autonomous Region, People's Republic of China
  • Mean Systolic Hypertension (≥ 140 mmHg)

Exclusion Criteria:

  • Currently taking any potassium supplements (or lives in household where someone does)
  • Previously diagnosed kidney disease or gout (or lives in a household where someone does) and physician considered he/she cannot take salt substitute.
  • Any person who intended to use salt outside the assigned treatment salt provide in the study

Sites / Locations

  • Dangxiong People's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Normal Salt

Salt Substitute

Arm Description

100% Sodium Chloride

65% Sodium Chloride, 25% Potassium Chloride, 10% Magnesium Sulphate)

Outcomes

Primary Outcome Measures

Change in Baseline Mean Systolic Blood Pressure (mmHg) at 6 months
3 Serial in Right Arm with Seated Patients with at least 1 minute between measurements using Omron 751 Automated Cuff.

Secondary Outcome Measures

Percent of patients having blood pressure under control (<140/90 mmHg)
Change in Baseline Mean Systolic Blood Pressure (mmHg) at 3 months.
3 Serial in Right Arm with Seated Patients with at least 1 minute between measurements using Omron 751 Automated Cuff

Full Information

First Posted
August 31, 2011
Last Updated
July 27, 2016
Sponsor
The George Institute for Global Health, China
Collaborators
Peking University, Beijing Jishuitan Hospital, People's Hospital of Dangxiong County
search

1. Study Identification

Unique Protocol Identification Number
NCT01429246
Brief Title
China Salt Substitute Study in Tibet
Acronym
CSSS-Tibet
Official Title
China Salt Substitute Study in Tibet: Efficacy of Salt Substitute in Reducing Blood Pressure in Hypertensive Adults
Study Type
Interventional

2. Study Status

Record Verification Date
September 2011
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
August 2009 (Actual)
Study Completion Date
August 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The George Institute for Global Health, China
Collaborators
Peking University, Beijing Jishuitan Hospital, People's Hospital of Dangxiong County

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study was a single-blind randomized controlled trial conducted between February and August 2009 in two townships (Yangbajing and Gongtang) of Dangxiong County, an area at 4300 meters altitude in Tibet. A brief baseline survey and assessment for eligibility was performed before randomization. A total of 282 residents with known hypertension (systolic blood pressure ≥ 140mmHg) were recruited and randomly assigned to intervention or control with stratification by gender and baseline blood pressure. The intervention group received 6-month's supply of salt substitute (68% sodium chloride, 22% potassium chloride and 10% magnesium sulfate heptahydrate) and the control group 6-month's supply of regular salt (100% sodium chloride). After 3-month's intervention, the ones with a blood pressure above 140 mmHg / 90 mmHg will be given low-dose diuretic for further anti-hypertensive therapy. The study hypothesis is that salt-substitute will greatly reduce blood pressure in treated patients when compared to controls. Blood pressure levels were measured at baseline and followed up by trained observers using an automated sphygmomanometer and brief survey on level of compliance, amount of salt consumed, and reasons for non-compliance.
Detailed Description
Hypertension is one of the most important risk factors that induce cardiovascular and cerebrovascular disease. Reducing the blood pressure levels of population can not only control the incidence of cardiovascular and cerebrovascular disease effectively, but also reduce the mortality. Anti-hypertension drug therapy has been proven to be an effective method to reduce blood pressure. Dietary sodium restriction and potassium supplementation is the core of dietary approaches to stop hypertension. Tibet is located on the Tibetan Plateau with an average altitude about 4000 meters above sea level. Tibetan diet is rich in meat but poor in vegetables and fruits. Salt intake is quite high due to habitual drinking of salty butter tea. Former national surveys showed a high prevalence of hypertension in Tibet. The investigators conducted this randomized controlled intervention study to test whether the investigators can offer a cost effective way to lower blood pressure and control hypertension in a sample of subjects from Yangbajing and Gongtang in Dangxiong County, Lhasa, Tibet. A randomized controlled trial was conducted in Yangbajing Township and Gongtang Village in the Dangxiong county , Tibet. A total of 282 hypertensive patients were chosen as study subjects. The regular salt or salt substitution were randomly allocated to the two groups. The whole intervention last for 6 months, with Phase 1 for three months and a following Phase 2 for another three months. For Phase 1, the study subjects were allocated the regular salt or the salt substitute after a randomization. For Phase 2, the study subjects continued the intervention of regular salt or salt substitute while the ones with a blood pressure above 140mmHg/90 mmHg will be given low-dose diuretic for further anti-hypertensive therapy. During the whole intervention period, the study subjects were not informed of what kind of salt they were taking. Blood pressure was the major outcome and would be measured at baseline, 3 months and 6 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Diet Therapy, Sodium Chloride, Dietary, Tibet, Aged

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
282 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Normal Salt
Arm Type
Active Comparator
Arm Description
100% Sodium Chloride
Arm Title
Salt Substitute
Arm Type
Experimental
Arm Description
65% Sodium Chloride, 25% Potassium Chloride, 10% Magnesium Sulphate)
Intervention Type
Dietary Supplement
Intervention Name(s)
Regular Salt
Intervention Description
Estimated Household Individual Consumption of 30 grams per day
Intervention Type
Dietary Supplement
Intervention Name(s)
Salt Substitute
Intervention Description
Estimated 30 grams per day per household member
Primary Outcome Measure Information:
Title
Change in Baseline Mean Systolic Blood Pressure (mmHg) at 6 months
Description
3 Serial in Right Arm with Seated Patients with at least 1 minute between measurements using Omron 751 Automated Cuff.
Time Frame
(Baseline compared to 6 months after start of intervention)
Secondary Outcome Measure Information:
Title
Percent of patients having blood pressure under control (<140/90 mmHg)
Time Frame
Baseline, and post start of intervention at 3 months and 6 months
Title
Change in Baseline Mean Systolic Blood Pressure (mmHg) at 3 months.
Description
3 Serial in Right Arm with Seated Patients with at least 1 minute between measurements using Omron 751 Automated Cuff
Time Frame
(Baseline compared to 3 months after start of intervention)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 40 years or older Resident of Yangbajing Township and Gongtang Village in Tibetan Autonomous Region, People's Republic of China Mean Systolic Hypertension (≥ 140 mmHg) Exclusion Criteria: Currently taking any potassium supplements (or lives in household where someone does) Previously diagnosed kidney disease or gout (or lives in a household where someone does) and physician considered he/she cannot take salt substitute. Any person who intended to use salt outside the assigned treatment salt provide in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yangfeng Wu, PhD
Organizational Affiliation
The George Institute, China (Beijing, CN)
Official's Role
Study Director
Facility Information:
Facility Name
Dangxiong People's Hospital
City
Lhasa
State/Province
Tibet
ZIP/Postal Code
850000
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
8746640
Citation
Tian HG, Guo ZY, Hu G, Yu SJ, Sun W, Pietinen P, Nissinen A. Changes in sodium intake and blood pressure in a community-based intervention project in China. J Hum Hypertens. 1995 Dec;9(12):959-68.
Results Reference
background
PubMed Identifier
14974027
Citation
Hooper L, Bartlett C, Davey SG, Ebrahim S. Advice to reduce dietary salt for prevention of cardiovascular disease. Cochrane Database Syst Rev. 2004;(1):CD003656. doi: 10.1002/14651858.CD003656.pub2.
Results Reference
background
PubMed Identifier
15266549
Citation
He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2004;(3):CD004937. doi: 10.1002/14651858.CD004937.
Results Reference
background
PubMed Identifier
17885542
Citation
China Salt Substitute Study Collaborative Group. Salt substitution: a low-cost strategy for blood pressure control among rural Chinese. A randomized, controlled trial. J Hypertens. 2007 Oct;25(10):2011-8. doi: 10.1097/HJH.0b013e3282b9714b.
Results Reference
background
PubMed Identifier
19661926
Citation
Zhou X, Liu JX, Shi R, Yang N, Song DL, Pang W, Li YM. Compound ion salt, a novel low-sodium salt substitute: from animal study to community-based population trial. Am J Hypertens. 2009 Sep;22(9):934-42. doi: 10.1038/ajh.2009.135. Epub 2009 Aug 6.
Results Reference
background
PubMed Identifier
18227813
Citation
He FJ, MacGregor GA. Can a low-sodium, high-potassium salt substitute reduce blood pressure in rural Chinese people? Nat Clin Pract Cardiovasc Med. 2008 Apr;5(4):186-7. doi: 10.1038/ncpcardio1122. Epub 2008 Jan 29. No abstract available.
Results Reference
background
PubMed Identifier
19262499
Citation
Hu J, Jiang X, Li N, Yu X, Perkovic V, Chen B, Zhao L, Neal B, Wu Y. Effects of salt substitute on pulse wave analysis among individuals at high cardiovascular risk in rural China: a randomized controlled trial. Hypertens Res. 2009 Apr;32(4):282-8. doi: 10.1038/hr.2009.7. Epub 2009 Feb 27.
Results Reference
background
PubMed Identifier
18710605
Citation
Li N, Prescott J, Wu Y, Barzi F, Yu X, Zhao L, Neal B; China Salt Substitute Study Collaborative Group. The effects of a reduced-sodium, high-potassium salt substitute on food taste and acceptability in rural northern China. Br J Nutr. 2009 Apr;101(7):1088-93. doi: 10.1017/S0007114508042360. Epub 2008 Aug 19.
Results Reference
background
PubMed Identifier
25338053
Citation
Zhao X, Yin X, Li X, Yan LL, Lam CT, Li S, He F, Xie W, Sang B, Luobu G, Ke L, Wu Y. Using a low-sodium, high-potassium salt substitute to reduce blood pressure among Tibetans with high blood pressure: a patient-blinded randomized controlled trial. PLoS One. 2014 Oct 22;9(10):e110131. doi: 10.1371/journal.pone.0110131. eCollection 2014.
Results Reference
derived

Learn more about this trial

China Salt Substitute Study in Tibet

We'll reach out to this number within 24 hrs